Acquisitions (Details Textual) |
1 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Oct. 01, 2021
USD ($)
shares
|
Oct. 01, 2021
USD ($)
shares
|
Apr. 01, 2021
USD ($)
shares
|
Jul. 07, 2020
USD ($)
|
Apr. 11, 2020
USD ($)
|
Jan. 30, 2020
USD ($)
|
Jan. 15, 2020
USD ($)
$ / shares
shares
|
Dec. 31, 2021
USD ($)
|
Sep. 30, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
$ / shares
shares
|
Dec. 31, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
$ / shares
shares
|
Jun. 30, 2020
USD ($)
|
Dec. 31, 2021
CAD ($)
shares
|
Dec. 31, 2021
USD ($)
$ / shares
shares
|
Sep. 01, 2020
shares
|
Jul. 31, 2020
shares
|
Apr. 08, 2020
USD ($)
$ / shares
shares
|
|
Business Acquisition [Line Items] | ||||||||||||||||||
Common stock, shares issued | shares | 1 | 1,950,000 | 31,001,884 | 31,001,884 | 31,001,884 | 31,001,884 | 800,000 | |||||||||||
Convertible into shares of common stock per share | $ / shares | $ 9 | |||||||||||||||||
Amortization expense of intangible assets | $ 5,600,000 | $ 1.8 | $ 1,300,000 | |||||||||||||||
Revenues | $ 2,400,000 | $ 7,824,784 | 20,684,974 | 12,573,276 | ||||||||||||||
Net income (loss) | $ 400,000 | $ (16,210,481) | (31,328,711) | (13,572,311) | ||||||||||||||
Preferred stock, par value | $ / shares | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||
Preferred stock, liquidation preference per share | $ / shares | $ 1 | |||||||||||||||||
Exchangeable shares | shares | 627,225 | |||||||||||||||||
Exchangeable shares issued | shares | 309,286 | 309,286 | 4,798,271 | |||||||||||||||
Assets and liability acquired | $ 14,300 | |||||||||||||||||
General and administrative expenses | 1.1 | $ 1.8 | ||||||||||||||||
Goodwill and intangible assets impairment | $ 14.4 | |||||||||||||||||
Contingent consideration | 6,300,000 | |||||||||||||||||
Common stock issued in business combinations | 20,081,466 | |||||||||||||||||
Cash | $ 445,269 | 445,269 | 527,346 | |||||||||||||||
Trellis Solutions, Inc [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Transaction costs | $ 100,000 | |||||||||||||||||
Common stock, shares issued | shares | 349,650 | |||||||||||||||||
Convertible into shares of common stock per share | $ / shares | $ 7.24 | |||||||||||||||||
Percentage of exchange rate | 100.00% | |||||||||||||||||
Amount of contingent consideration liability | $ 1 | |||||||||||||||||
Revenues | $ 216,000 | |||||||||||||||||
Net income (loss) | $ 17,000 | |||||||||||||||||
Contingent consideration | $ 0 | 998,000 | ||||||||||||||||
Cash | $ 21 | |||||||||||||||||
Solo Sciences, Inc. [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Transaction costs | $ 300,000 | |||||||||||||||||
Percentage of exchange rate | 80.40% | |||||||||||||||||
Description of contingent consideration | (i) $0.01 per solo*TAG™ and solo*CODE™ sold or (ii) 7% of net revenue. The fees were to be paid annually until the earlier of: (1) our shares trading above $12 per share for any consecutive 20 trading days in a 30-day period; (b) upon our no longer owning a majority stake in Solo; or (c) upon expiration of the patents related to solo*TAG™ and solo*CODE™, which is December 1, 2029. | |||||||||||||||||
Estimated of fair value contingent consideration | $ 17.9 | |||||||||||||||||
Revenues | $ 23,000 | |||||||||||||||||
Net income (loss) | $ 1,500,000 | |||||||||||||||||
Goodwill and intangible assets impairment | $ 2,700,000 | |||||||||||||||||
Contingent consideration | 389,000 | |||||||||||||||||
Cash | $ 101 | |||||||||||||||||
Solo Sciences, Inc. [Member] | Maximum [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Percentage of exchange rate | 55.00% | 55.00% | ||||||||||||||||
Solo Sciences, Inc. [Member] | Minimum [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Percentage of exchange rate | 40.00% | 40.00% | ||||||||||||||||
Ample Organics [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Transaction costs | 2,900,000 | |||||||||||||||||
Revenues | 2,600,000 | |||||||||||||||||
Net income (loss) | 100,000 | |||||||||||||||||
Acquisition of description | acquired 100% of the stock of Ample Organics for 3.3 million exchangeable shares of one of our wholly-owned subsidiaries. The exchangeable shares may be exchanged, at the option of the holder, for shares of Akerna common stock on a one-for-one basis, therefore the exchangeable shares issued were valued at $7.65 per share, the closing price of an equivalent share of Akerna common stock, $30.7 million was the aggregate value of the exchangeable shares. In addition to the stock consideration, we paid $5.5 million in cash, which was used to settle all of Ample's then outstanding debt. In addition to the stock and cash consideration, the agreement provides for contingent consideration of up to CAD$10,000,000, payable in exchangeable shares, payable if Ample's Recurring Revenue recognized during the 12 months after the acquisition date is CAD$9,000,000 or more. The contingent consideration amount is reduced by an amount equal to the product of CAD$6.67 multiplied by the difference between CAD$9,000,000 and the amount of Recurring Revenue realized during the 12 months following the acquisition. | |||||||||||||||||
Goodwill and intangible assets impairment | $ 4,200,000 | |||||||||||||||||
Contingent consideration | $ 10,000,000 | 604,000 | ||||||||||||||||
Cash | $ 445 | |||||||||||||||||
Viridian Sciences Inc. [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Revenues | $ 2,400,000 | |||||||||||||||||
Net income (loss) | $ 300,000 | |||||||||||||||||
Exchange shares value | $ 6,000,000 | |||||||||||||||||
Contingent consideration | $ 1,000,000 | 2,000 | ||||||||||||||||
Cannabis [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Contingent consideration | 6,300,000 | |||||||||||||||||
Common stock issued in business combinations | $ 12,000,000 | |||||||||||||||||
Cash | 5,000,000 | 5,000,000 | ||||||||||||||||
Aggregate stock price | $ 8,000,000 | $ 8,000,000 | ||||||||||||||||
Viridian [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Contingent consideration | $ 2,000 | |||||||||||||||||
365 Cannabis [Member] | ||||||||||||||||||
Business Acquisition [Line Items] | ||||||||||||||||||
Common stock, shares issued | shares | 3,600,000 | 3,600,000 | ||||||||||||||||
Cash | $ 527 | $ 527 |